/qrb/ - QResearch Bunker

Globals

HELP WANTED: If you want to learn to bake let us know

>>77592 Rusty/Q thread NEW

>>74385 BITCHUTE embedding now enabled in 8 new

>>71855 Archive QR deletions here

>>69095 Guidelines on CP, what to report in addition to illegal images

Notables

are not endorsements

#482

>>79236, >>79260 CodeMonkeyZ BOMBSHELL- Dominion Whistleblower Speaks Out – Releases Admin Password Proving Remote Access –VIDEO

>>79238 President Biden calls on New York Governor Cuomo to resign

>>79245 House Republicans protest the mask mandate in the Senate

>>79246 Italy parliament in an uproar over "Green Pass" vax passports

>>79247 Reporter to Biden - why are the unvaxxed allowed to enter the country?

>>79248 FINAL LIST OF STATE CHATS - Election Audits

>>79249, >>79254 The Five Doctors: Dr. Lee Merritt, Dr. Christiane Northrup, Dr. Carrie Madje, Dr. Sherri Tenpenny, and Dr. Larry Palevsky

>>79251 NY VACCINE PASSPORT IS THE HILL TO DIE ON

>>79252 The Atlantic thinks unvaxxed people should be on NO-FLY list ("they want us dead")

>>79253 Army gives Pfizer $3.5B contract to make 500 million COVID vaccine doses

>>79255 Giuliani: The Covid Rich Get Richer

>>79256 Giluliani: All Lies Will Be Revealed

>>79257 About half of all new covid cases are vaxxed (UK)

>>79258 Iceland and Singapore lift all coronavirus restrictions

>>79259 Upcoming events: the heat is being turned up

>>79261 McCloskeys pardoned by Missouri Governor over last year's viral incident

>>79268 #482

#481

>>79169, >>79194, >>79202, >>79204 Eyez on the skyz

>>79216 Chinese national plead guilty in money laundering scheme connected to El Chapo’s cartel

>>79215 Tyson Foods will require all U.S. employees to be vaccinated by November

>>79210, >>79211 LATEST FROM ARCHBISHOP VIGANO ON THE VACCINES AS CHILD SACRIFICE

>>79203 Devolution - Part 7 - Foreign Interference

>>79201 Biden Infrastructure Bill Mandates Drunk-Driver Detector Surveillance Systems For New Cars

>>79200 Eric Rosenbach, CENTER of the electronic voting fraud

>>79198 VIRGINIA! multiple Counties where fraudis almost certain, Audits will prove

>>79189 45: congrats to Carey in Ohio win

>>79182 massive exercise will span 17 time zones with sailors and Marines in the U.S., Africa, Europe and the Pacific joining.

>>79178, >>79180, >>79184, >>79195 CM: Remote Access?

>>79177, >>79179, >>79183 U.S. Banking System Has a $168 Trillion Nightmare Looming. It Was Ignored in Written Testimony for Today’s Senate Banking Hearing

>>79176 Law of War guy

>>79174 GOP Senator Introduces Bill To Require States That Mandate Vaccine Passports To Also Mandate Voter ID

>>79173 ELITE GOVENERS AND CUOMO COMMS FROM Q

>>79172, >>79196, >>79197, >>79214 PROMINENT DEMS CALLING FOR @NYGovCuomo TO RESIGN:/RudyG rebutts

>>79171 FDA Authorizes Antibody Cocktail as COVID-19 Prevention Treatment

>>79170 Lockheed Martin CFO Abruptly Retires For ‘Personal Reasons’

>>79168 Virginia Group Looks to Recall Radical Soros-Backed Prosecutors

>>79167 Mr. Cooper Group, Inc. sold by Kohlberg, Kravis, Roberts & Co.: $368.18m-Aug 2

>>79162 Germany preppin lockdown

>>79161 CDC has no authority to issue eviction mandates

>>79160, >>79166 ANTIFA CHAT LOGS

>>79154 America’s Tamyra Mensah-Stock won gold at Tokyo in wrestling: She's Awesome!

>>79218 #481

#480

>>79077, >>79088, >>79103, >>79108, >>79112, >>79124, >>79130, >>79139 Tongue Out Tuesday planefaggin

>>79142, >>79144 Pompeo/Q/Cuba

>>79136 After Claiming Hands Tied, Biden Admin To Issue 'Targeted' Eviction Ban

>>79131, >>79132 45 WH on road to financial ruin, Seth Keshel

>>79129 Is it Huma?

>>79122 Maggie on Cuomo losing union support

>>79119 US household debt surged to nearly $15T in second quarter, a new record

>>79117 Airports From Nantucket To California Suffer Jet Fuel Shortages

>>79115, >>79120, >>79121 WHY IS THIS PICTURE INCLUDED IN THE GOVERNOR’S RESPONSE???

>>79111, >>79113 Cuomo released his response on his webpage.

>>79105 Book is being thrown/AZ audit

>>79104 mail in recall kekked

>>79096 Pentagon reopens following shooting, stabbing incident, no deets

>>79093, >>79094 Dr. Shiva Discovers Existence of the Secretive Long Fuse Report

>>79092 1:12 Delta/Q

>>79089, >>79095, >>79140 Calls for Cuomo to resign

>>79086 The USA is not the only Country in the World using Dominion / Smartmatic voting machines.

>>79082 Scientific Journal Paper Suggests Making It A ‘Federal Hate Crime’ To Criticize Fauci.

>>79080 U.S. overnight repo rate elevated after Monday's funding pressure

>>79079 Absolute Proof vid

>>79145 #480

#479

>>79026 Tungz Out Tuesday planefaggin

>>79065 EMA Vaxzevria / AstraZeneca - Produkt information

>>79064 Microsoft to Require Vaccinations to Enter U.S. Offices

>>79062 @AFResearchLab is building an advanced high-power microwave weapon system

>>79061, >>79063 Colorado Sec. of State Moves to Eliminate Signature Verification, ‘Protect’ Dead Voters and Put Gag Order on Poll Workers

>>79060 Titanic news today

>>79058 The #USCG released an updated Cyber Strategic Outlook today to address the rising threat of cyber-attacks against critical maritime systems

>>79053 This is at least the 2nd time the IG found a senior FBI official "violated federal regulations" accepting gifts from journalists

>>79052 Can we just take a moment to appreciate just how powerful CM's social influence has become to......................

>>79048 Japan government starts to 'name and shame' quarantine rule-breakers

>>79046, >>79047, >>79049, >>79051 CORONA is America's first successful photographic reconnaissance satellite #HISTINT #Museum

>>79044, >>79045 The Deep Rig is now FREE to watch, gotta sign in though

>>79043 Ever Given: Cargo ship that blocked Suez Canal arrives in Felixstowe

>>79035 Duolingo, Inc sold by CapitalG (formerly Google Capital): $36.32m-July 30

>>79034 ECW: Iran's drone attack killed two European civilians. That's a terrorist attack.

>>79032 If the AZGOP solicited donations for the Maricopa forensic audit, why didnt they send money?

>>79031 @USArmy Increasing Soldier #lethality!

>>79029, >>79030 Economist chooses Satan to chair their meetings

>>79024 4th 1/6 suicide reported was on July 10

>>79022 NYC to Require Citizens to Show Vaccine Papers

>>79020, >>79021, >>79027 Moar Pentagon lockdown

>>79018, >>79019 ,>>79041 CM vid, Katie Hobbs has the password, so does CM

>>79017, >>79028 from 2 then to 4 ships off the coast of the UAE are broadcasting warnings that they have lost control of their steering

>>79016 Pompeo/Q For God and Country

>>79015, >>79039 NY AG finds Cuomo guilty

>>79010 Florida takes action against Ben & Jerry's parent company amid fight over Israel

>>79001, >>79006 666 skank

>>79066 #479

Previously Collected Notables:

>>78736 #475, >>78825 #476, >>78904 #477, >>78989 #478

>>78069 #469, >>78199 #470, >>78333 #471, >>78459 #472, >>78517 #473, >>78631 #474

>>77465 #463, >>77547 #464, >>77647 #465, >>77724 #466, >>77839 #467, >>77985 #468

QRB notables archived here >>>/qrb/9528

Notables aggregator https://wearethene.ws

Notables aggregator https://qnotables.com

Meme Ammo

>>>/qrmemes/ One-stop Meme Board, organized by topic

>>>/qrb/57489 Digital Camo Thread Archive

>>>/qrmemes/606 Meme Camo Thread

Dedicated Research Threads

>>>/qresearch/14121360 Clockwork Qrange #13

>>>/qrb/13005 Planefagging 101 Q&A

>>>/qrb/42185 Boatfagging Q&A

>>>/qrb/22979 Information Warfare II

>>>/comms/12299 Oregon, Washington, I-5 Corridor: Turn the Tide

>>>/comms/26525 Exposing Media Lies about Q: Post Attacks Against Q here

International Q Research Threads

>>>/qresearch/14019901 ————————————–——– Australia #17

>>>/qresearch/13323637 ————————————–——– Balkan #8

>>>/qresearch/13167439 ————————————–——– Brazil #2

>>>/qresearch/14080238 ————————————–——– Canada #22

>>>/qresearch/13269960 ————————————–——– France #4

>>>/qresearch/14166186 ————————————–——– Germany #84

>>>/qresearch/13187313 ————————————–——– Italia #2

>>>/qresearch/13226402 ————————————–——– Japan #2

>>>/qresearch/13410974 ————————————–——– Mexico #3

>>>/qresearch/13105482 ————————————–——– Nederland #6

>>>/qresearch/13163282 ————————————–——– New Zealand #8

>>>/qresearch/13163911 ————————————–——– Nordic #3

>>>/qresearch/13163805 ————————————–——– Russia #2

>>>/qresearch/13163650 ————————————–——– Scotland #4

>>>/qresearch/14081815 ————————————–——– South Africa #6

>>>/qresearch/13991348 ————————————–——– UK #40

Q Proofs & Posts

Q Proofs Threads Proofs of Q's Validity >>>/qresearch/6156082

Book of Q Proofs https://mega.nz/#F!afISyCoY!6N1lY_fcYFOz4OQpT82p2w - https://bookofqproofs.wordpress.com/

Storm is here Q Posts Q&A & all images bu docs.google.com/spreadsheets/d/1Efm2AcuMJ7whuuB6T7ouOIwrE_9S-1vDJLAXIVPZU2g/

Q & POTUS timestamps docs.google.com/spreadsheets/d/1OqTR0hPipmL9NE4u_JAzBiWXov3YYOIZIw6nPe3t4wo/

Q Happenings Calendar

Submit an event here https://teamup.com/ks8x4ixptej432xt2a

Main Calendar URL https://dark-to-light.org/calendar/

Sealed Indictments

Sealed Indictment Master https://docs.google.com/spreadsheets/d/1kVQwX9l9HJ5F76x05ic_YnU_Z5yiVS96LbzAOP66EzA/edit#gid=1525422677

Sealed Indictment Master Files Backup https://drive.google.com/open?id=1iBS4WgngH8u8-wAqhehRIWCVBQKD8-5Y

Searchable Indictment Map w/dockets, links & more https://bad-boys.us/

Resignations

All Resignations Website https://www.resignation.info

All Posts Search Tool https://qresear.ch

Q Graphics

Q Graphics all in GMT >>>/qrb/57490, #001 and scroll down >>>/comms/283

Original, full-size images Q has posted postimg.cc/gallery/29wdmgyze/

Tweet Tools

All My Tweets - Archive/Scan any Twatter account in text form www.allmytweets.net/

Twitter Video Downloader twittervideodownloader.com/

Deleted Trump Tweets factba.se/topic/deleted-tweets

Trump Tweet Archive trumptwitterarchive.com

Archives & Archivers

Archivers for Firefox, Opera & Webpage >>57496

QRB General Archive archive8kun.top/qrb/archive/index.html

(only activated for breads fallen off the catalog)

QR - MasterArchivist masterarchivist.github.io/qarchives/

QR - MasterArchivist (supplement) (main spreadsheet, 2nd tab, labeled)

https://docs.google.com/spreadsheets/d/1M2AzhZKh2PjL7L7GVPN42Em0hZXKWMdhGnj59ZQ3YcQ/

QR - GermanArchiveAnon mega.nz/folder/LPZxEIYJ#N5JwCNoxOxOtAoErKdUgvw

Wayback Machine for old archived websites https://web.archive.org

Webpage Archiver: http://archive.md/

Other Tools

500 videos from the Capital on Jan 6' >>67804 new

Advanced Google Search Operators ahrefs.com/blog/google-advanced-search-operators/

Biden's destruction of America - first 100 days >>58856

Commercial Aviation Incident List avherald.com

Criminal Cases Database https://www.justice.gov/usao/find-r-united-states-attorney

DMCA takedown notice or abuse report reporting@isitwetyet.com.

Federal Judicial Court Dataset from 93 Federal Districts - Searchable db '''bad-boys.us/

Federal Procurement Data System www.fpds.gov/fpdsng_cms/index.php/en/

Hosts File (DNS), How to Edit >>>/comms/4396

Hussein WH visitor list qest.us/obamavisitors

Legal News www.justice.gov/usao/pressreleases

Links to Alt-Media (Contacts, Websites) >>51758

Q Boards/Sites >>58867

Qcode Guide to Abbreviations pastebin.com/UhK5tkgb

Research Section Backup >>>/comms/220 (updated 1.12.19)

Reverse image search to sauce https://tineye.com/

Stock Movement Scraper qest.us (for seeing LARGE movements of $)

Staff Notes

BO changes/board updates >>57468, >>57469, >>57470, >>57471, >>57472, >>57473

Notables - plz list more often at end of bread >>57493

Passwords in fullchan.net - do not use >>57494

QRB baking - watch for a lag >>57495

QRB content policy >>57466

Wearethene.ws formatting >>57477, >>57480, >>57481, >>57482, >>57483, >>57484, >>57485, >>57486, >>57481, >>57484

Learn To Bake!

Quick Pic Bakes & E-bake instructions >>57491, https://pastebin.com/aY5LyDPY, >>>/comms/9252

Resources from last LIVE Baking Class #39 >>>/comms/40980 (step by step baking instructions)

Baker Tools - several versions >>58368

How to format multi-page notables https://qanonbin.com/paste/0kIGTHWjd

Tips on Notables for Bakers >>>/comms/41080

Iwo Jima flag on YouTube for TOR posting https://tu.be/9E3uBWn7e8U

>>79279

morn'n and habby wednesday.

>>79279

[their] day is coming.

justice will prevail and they definitely won't be able to walk down the street when it all shakes out.

>>79284

anons will migrate. it should be organic. all guud.

>>79286

yo bro.

cloudy here. wind pickn up too.

rough irl for me today. sorry to dump on you, but from 11 on i am wurkfagg'n.

>>79288

dem 8s

morn'n gb. habby wenzday

>>79288

mornin G

rollin dubs first thing

gonna be a guud day

howza

>>79290

oldest got in some trubble yesterday.

big trubble. wakes no habby rn

>>79292

>>79292

oh wakers

prayers yo

muh youngest, greys, wrinkles, tude

no kek

gotz ears if ya need em

>>79295

thx bro

quiet notables bun @30

cakes, i gotta book. can you take over?

#483

>>79288 planefagg'n

>>79299 Fed's Clarida backs raising interest rates in 2023

>>79282 Vote to Remove Gavin Newsom Within Margin of Error; Hispanics Favor Recall

>>79292

sorry to hear

rough time for youth (always rough but more so now, too much pressure for young ones)

Blessings to you and your fam, friend.

bz

>>79321

(by 'youth' i don't mean just 16 year olds - dey stay young for a long time after dat, just don know it)

>>79322

still see'n baby steps

just not for walkin

>>79305

>wtube

hope it's as good as it sounds

i hate signing into anything anymore

dey gonna have to have people watching for illegal stuff tho

>>79325

was hoping someone would trace it down

cloudfare, which can be cut on a dime?

always leary of copycats

everybody and thing too

kek

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892316/

Autoimmun Rev. 2021 Apr; 20(4): 102792.

Published online 2021 Feb 19. doi: 10.1016/j.autrev.2021.102792

PMCID: PMC7892316

PMID: 33610751

The SARS-CoV-2 as an instrumental trigger of autoimmunity

Abstract

Autoimmunity may be generated by a variety of factors by creating a hyper-stimulated state of the immune system. It had been established long ago that viruses are a substantial component of environmental factors that contribute to the production of autoimmune antibodies, as well as autoimmune diseases. Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human immunodeficiency virus (HIV) are viruses that withhold these autoimmune abilities. In a similar manner, SARS-CoV-2 may be counted to similar manifestations, as numerous records demonstrating the likelihood of COVID-19 patients to develop multiple types of autoantibodies and autoimmune diseases. In this review, we focused onthe association between COVID-19 and the immune systemconcerningthe tendency of patients to develop over 15 separate types of autoantibodies and above 10 distinct autoimmune diseases. Anadditional autoimmunity manifestationmay be one of the common initial symptoms in COVID-19 patients,anosmia, the complete loss of the ability to sense smell, and other olfactory alterations. We summarize current knowledge on principal mechanisms that may contribute to the development of autoimmunity in the disease:the ability of SARS-CoV-2 to hyper-stimulate the immune system, induce excessive neutrophil extracellular traps formation with neutrophil-associated cytokine responses and the molecular resemblance between self-components of the host and the virus. Additionally, we will examineCOVID-19 potential risk on the new-onsets of autoimmune diseases, such asantiphospholipid syndrome, Guillain-Barré syndrome, Kawasaki disease and numerous others. It is of great importance to recognize thoseautoimmune manifestations of COVID-19in order to properly cope with their outcomes in the ongoing pandemic and the long-term post-pandemic period. Lastly, an effective vaccine against SARS-CoV-2 may be the best solution in dealing with the ongoing pandemic. We will discuss the new messenger RNA vaccination strategy with an emphasis on autoimmunity implications.

#483

>>79288, >>79303, >>79312, >>79313, >>79315, >>79316 Eyez to the skyz

>>79330 Mexico Sues Smith & Wesson and Glock Over Smuggled Firearms

>>79329 The SARS-CoV-2 as an instrumental trigger of autoimmunity

>>79328 Our office recently fought a similar legal challenge to Arizona's election integrity measures and won in the #SCOTUS case 𝑩𝒓𝒏𝒐𝒗𝒊𝒄𝒉 𝒗. 𝑫𝑵𝑪.

>>79326 45 talking congressional wins

>>79314, >>79317 @ORNL, which just got a shipment of advanced fuel rods that went through testing in a commercial reactor.

>>79312 Boeing 737 Max heads to China for key test to end flight ban

>>79309 This is the actual results of the Elections. H/T Scooby Snacks.

>>79307 Baker Hughes Company sold by General Electric Co.: $1.254B-August 3

>>79306 Rebels were, "too powerful to be suppressed by the powers vested in the Marshal of that District." Washington called out the state militias.

>>79305 Introducing wtube.org

>>79299 Fed's Clarida backs raising interest rates in 2023

>>79282 Vote to Remove Gavin Newsom Within Margin of Error; Hispanics Favor Recall

#483

quick collect

feelin tired

lemme rest for a bit

back to collect and bake

Moar QUANT FAMILY (Amazing Polly)

IMPORTANT!!!!!

Direct connection to now just PCR Fraud Drosten, but also to his college Sandra Ciesek

https://www.bitchute.com/embed/yJyxhFswCnuZ/

ARCHIVE OFFLINE

>>79338

Back in February, the 42-year-old and her team were able to prove that even symptom-free individuals carry the coronavirus and can thus transmit it

And that seems to be fake science, see study from China.

Wow, these people were really fast. Drosten with his fraud PCR test and this bitch with her somehow finding out that there are infectious asymptomatic people.

>>79337

tx, anon.

i'll take notes on it, last Polly was great.

>>79342

We need to archive all of this asap.

And the other board members have to get looked at as well.

>>79346

Accomplishments

Jasmin has 10 publications 10

Publications

Wnt/β-catenin activation epigenetically reprograms Regulatory T cells in IBD and progression to dysplasia •BNT162b2induces SARS-CoV-2-neutralising antibodies and T cells in humans •Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine •TCF-1 and HEB cooperate to establish the epigenetic and transcription profiles of CD4+CD8+ thymocytes. •Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses •β-catenin signaling mediates pathogenic pro-inflammatory conversion of Foxp3+ Treg cells early during colon cancer development •NF-κB-dependent signals control BOB.1/OBF.1 and Oct2 transcriptional activity in B cells •A vaccine targeting mutant IDH1 induces antitumour immunity •T cell responses against mutations in oncoproteins/tumor suppressor proteins and their induction by vaccination with long peptides •Octamer-dependent transcription in T cells is mediated by NFAT and NF-κB

Jasmin has 5 courses 5

Courses

Basics in Economy (Grundlagen der Betriebswirtschaftslehre) •Development, permission, and controlling of drugs •Effective Writing for Life Science Research •FELASA B •Patentrecht

Jasmin has 3 languages 3

Languages

Deutsch •Englisch •Französisch

Jasmin has 2 honors 2

Honors & Awards

AAI (The American Association of Immunologists) Careers in Immunology Fellowship •CIMT 2011 Poster Award

Anyone got a linkedin account and can check her connections?

>>79348

sorry, no acct here

Wonder how common a name Quandt is in Germany?

>>79354

LINA BEHRENS

Managing Director at Flying Health GmbH, Berlin, Germany

Lina Behrens is a Managing Director at Flying Health, the leading ecosystem for Next Generation Healthcare. She is also Vice President of the German Startup Association and a Member of the Advisory Board „Junge Digitale Wirtschaft“ (Young Digital Economy) of the German Federal Ministry of Economics and Energy. Previously, Lina worked at the Boston Consulting Group (BCG) and at Polymath Ventures, one of the largest company builders in Latin America. Lina holds an MPA from the London School of Economics and a BA in Economics and in International Affairs from the University of St. Gallen.

JOHN S. BROWNSTEIN

Chief Innovation Officer at Boston Children’ Hospital, Boston, Massachusetts, USA

Professor of Biomedical Informatics at Harvard Medical School and is the Chief Innovation Officer of Boston Children’s Hospital. He also directs the Computational Epidemiology Lab and the Innovation and Digital Health Accelerator both at Boston Children’s. He was trained as an epidemiologist at Yale University. Overall, his work aims to have translation impact on the surveillance, control and prevention of disease. He has been at the forefront of the development and application of data mining and citizen science to public health. His efforts are in use by millions each year including the CDC, WHO, DHS, DOD, HHS, and EU, and has been recognized by the National Library of Congress and the Smithsonian. In addition to research achievements, this translational impact comes from playing an advisory role to numerous agencies on real-time public health surveillance including HHS, DHS, CDC, IOM, WHO and the White House. He was awarded the Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the United States government to outstanding scientists and the Lagrange Prize for international achievements in complexity sciences. Dr. Brownstein is co-founder of digital health companies Epidemico and Circulation and an ABC Medical News Contributor. He has authored over 250 peer-reviewed articles on epidemiology and public health. This work has been reported on widely including pieces in the New England Journal of Medicine, Science, Nature, New York Times, The Wall Street Journal, CNN, National Public Radio and the BBC.

>>79355

ARTHUR CAPLAN

Drs. William F and Virginia Connolly Mitty Chair Director, Division of Medical Ethics, NYU Grossman School of Medicine, NY USA

Currently the Drs. William F and Virginia Connolly Mitty Professor and founding head of the Division of Medical Ethics at NYU School of Medicine in New York City.

Prior to coming to NYU School of Medicine, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. Caplan has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics, the University of Pittsburgh, and Columbia University. He received his PhD from Columbia University.

Dr. Caplan is the author or editor of thirty-five books and over 800 papers in peer reviewed journals. His most recent books are Vaccination Ethics and Policy, (MIT Press, 2017 with Jason Schwartz) and, Getting to Good: Research Integrity in Biomedicine Springer, 2018 with Barbara Redman).

He has served on a number of national and international committees including as the chair of the National Cancer Institute Biobanking Ethics Working Group, chair of the Advisory Committee to the United Nations on Human Cloning; chair of the Advisory Committee to the Department of Health and Human Services on Blood Safety and Availability. He has also served on the Presidential Advisory Committee on Gulf War Illnesses, the special advisory committee to the International Olympic Committee on genetics and gene therapy, the Special Advisory Panel to the National Institutes of Mental Health on Human Experimentation on Vulnerable Subjects, the Wellcome Trust Advisory Panel on Research in Humanitarian Crises, and the co-director of the Joint Council of Europe/United Nations Study on Trafficking in Organs and Body Parts. He is the co-founder and a member of the ge2p2 global foundation.

Caplan has served since 2015 as the chairperson of the Compassionate Use Advisory Committee (CompAC), an independent group of internationally recognized medical experts, bioethicists and patient representatives which advises Johnson & Johnson’s Janssen Pharmaceuticals about requests for compassionate use of some of its investigational medicines.

Dr. Caplan is a regular commentator on bioethics and health care issues for WebMD/Medscape, WGBH radio in Boston, WOR radio in New York City and CNN. He appears frequently as a guest and commentator on various other national and international media outlets.

Dr. Caplan is the recipient of many awards and honors including the McGovern Medal of the American Medical Writers Association and the Franklin Award from the City of Philadelphia. He was a USA Today 2001 “Person of the Year and was described as one of the ten most influential people in science by Discover magazine in 2008. He has also been honored as one of the fifty most influential people in American health care by Modern Health Care magazine, one of the ten most influential people in America in biotechnology by the National Journal, one of the ten most influential people in the ethics of biotechnology by the editors of Nature Biotechnology, and one of the 100 most influential people in biotechnology by Scientific American magazine.

During the Covid-19 pandemic, he co-directs an advisory group on sports and recreation for the US Conference of Mayors, created a working group on coronavirus vaccine challenge studies, developed an ethical framework for distributing drugs and vaccines for J&J, helped develop rationing policies for NYU LMC and many other health systems, is a member of the WHO advisory committee on Covid, ethics and experimental drugs/vaccines, helped set policy for WIRB/WCG for research studies He was an advisor to Moderna. And serves on the NCAA Sports and Covid committee.

He received the Patricia Price Browne Prize in Biomedical Ethics for 2011. In 2014 he was selected to receive the Public Service Award from the National Science Foundation/National Science Board, which honors individuals and groups that have made substantial contributions to increasing public understanding of science and engineering in the United States. In 2016 the National Organization for Rare Disorders (NORD) honored him with their Rare Impact Award and hFood and Drug Law Institute’s Distinguished Service Leadership Award. In 2019 he was honored by the Food and Drug Administration’s, Reagan/Udall Foundation with its Innovation Award.

He holds seven honorary degrees from colleges and medical schools.

>>79356

HORST DOMDEY

Managing Director at BioM Biotech Cluster Development GmbH, Planegg, Germany

In his scientific career, Horst Domdey worked at various German, Swiss and US institutes such as the Max Planck Institute of Biochemistry, the Swiss Institute of Cancer Research, the University of California at San Diego, the California Institute of Technology and the Munich Gene Center, where he was appointed as Professor of Biochemistry in 1994. In 1996 he successfully led the Munich Biotech Initiative into the German BioRegio Competition. Since 1997 he is the Managing Director of BioM, the development and management organization of the Munich Biotech Cluster, since 2006 he also directs the Bavarian Biotechnology Network. Among others he is a member of the boards of the Peter and Traudl Engelhorn Foundation and the Foundation for Stem Cell Research and Applied Regenerative Medicine.

GEORG N. DUDA

Founding director of Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies (BCRT) Charité - Universitätsmedizin Berlin, Germany

Georg is the founding director of the Julius Wolff Institute at the Charité, Humboldt University and Free University of Berlin. The Julius Wolff Institute brings together researchers from engineering, mathematics, biology, biochemistry and clinical scientists in order to develop new therapeutic strategies for regeneration of injured or degenerated joint, bones and muscles. Conceptually, Georg’s research aims at understanding endogenous cascades of tissue formation, cytokine signaling and cellular self-organization especially in bone. This understanding is transferred to enable regeneration in clinically challenging healing scenarios of tissues normally capable of regeneration (bone) and those with intrinsic impaired regenerative capacity. Mechanical straining and adaptation due to mechanical cues plays a central role in all these tissues. The aim of Georg’s work is to understand the mechano-biological cues of regeneration and adaptation and how they can be employed to enable healing even in tissues with impaired regenerative capacity such as muscle, cartilage or tendon. All approaches are motivated by clinical challenges, employ basic research principles and aim at being translated into daily clinical routine. Examples of translation include innovative concepts for joint replacement procedures, angle stable fixation of implants or cell therapies for muscle regeneration.

Given his broad interest, core to all his activities is the close collaboration with clinical partners, specifically the scientific education of clinical scientists as core members of his team of research.

Georg Duda is Professor of Biomechanics and Musculoskeletal Regeneration at the Charité – Humboldt University of Berlin and Free University of Berlin and an Associated Faculty Member at the Wyss Institute for Biologically Inspired Engineering at Harvard University. He received his Master’s degree in precision engineering from the Technical University of Berlin, Germany, in 1991 and his Ph.D. degree in Mechanical Engineering from the Technical University of Hamburg-Harburg in 1996. He has been recipient of over a dozen awards for inventions, start-up engagements and PhD student mentoring.

>>79357

DAME ANNA DOMINICZAK

Regius Professor of Medicine University of Glasgow, Scotland

Professor Dame Anna Dominiczak is Regius Professor of Medicine at the University of Glasgow; Honorary Consultant Physician and Endocrinologist at NHS Greater Glasgow and Clyde; and Health Innovation Champion for the Medical Research Council. In 2016, she was awarded a DBE for services to cardiovascular and medical science.

Professor Dominiczak is currently seconded to the Department of Health and Social Care in the UK Government as Director of Laboratories, NHS Test & Trace. In March 2020, she successfully led the establishment of the Lighthouse Laboratory in Glasgow (LLiG), leading to her current role where she continues to expand the Lighthouse laboratory network. She is accountable for the UK labs testing capability across a coordinated network of 13 labs. As the network continues to evolve, and very high throughput labs are brought online, Professor Dominiczak’s focus remains on delivering a triple helix partnership between academia, the NHS and industry to transform the long-term testing capability of the UK for COVID and beyond.

Recognised as a world-leading cardiovascular scientist and clinical academic, her major research interests are in hypertension, cardiovascular genomics and precision medicine, where she not only publishes extensively in top peer-reviewed journals (over 500 publications), but also excels in large scale research funding for programmes and infrastructure (with a total value in excess of £100M over the last eight years).

>>79358

MARC FILERMAN

Managing Partner at German Accelerator Life Sciences, Cambridge, Massachusetts, USA

Marc Filerman is a healthtech entrepreneur and intrapreneur with expertise in market development, commercialization, and innovation acceleration. He has broad experience leading marketing, sales, and business development for large companies and startups. Marc co-founded a molecular imaging startup, was Chief Commercial Officer at an NIH-funded hometech venture, and was an Accelerator Executive with the CIMIT accelerator at Massachusetts General Hospital. Prior to his entrepreneurial endeavors Marc held corporate leadership positions in multiple large healthtech companies, including VP of Global Marketing at iCAD, Group Director of Marketing at Smith & Nephew, and Director of Global Marketing and Strategy at Hill-Rom. Marc holds BS and MS degrees from MIT in Mechanical Engineering, did his graduate work at the MIT AI Lab, and started his career as an engineer designing ultrasound imaging equipment for echocardiography.

MEREDITH FISHER

Partner at Mass General Brigham Ventures, Cambridge, Massachusetts, USA

Dr. Meredith Fisher is a Partner with the Innovation Fund focusing on early stage investments and company creation. Previously, she was in the private office at Bracebridge Capital serving as Director of Private Investments where she led investments in early stage life science companies. Prior to that role she led business development for Ginkgo BioWorks- an MIT spin out- and was Senior Director of Technology and Business Development at PureTech Ventures. She spent several years working as a scientist in drug discovery and assay development for Idenix Pharmaceuticals and Anadys Pharmaceuticals. Meredith serves as a board member on Nocion, ClarisBio, ZielBio and Mediar Therapeutics where she is co-founding CEO. She is an Observer on Amolyt Pharma and Scorpion Therapeutics. Meredith received her undergraduate degree from Mount Holyoke College, her MBA from the MIT Sloan School of Management and her PhD from Harvard University.

>>79359

OLIVER HAYDEN

Heinz-Nixdorf-Chair of Biomedical Electronics, Director TranslaTUM at TU München, Germany

Employment

03/2019

Director of the Center for Translational Cancer Research (TranslaTUM), Campus University Hospital Klinikum rechts der Isar, TUM, Germany

06/2017

Heinz-Nixdorf-Chair of Biomedical Electronics, Department of Electrical and Computer Engineering, TU Munich, Germany

11/2016 - 05/2017

Head of In-Vitro Diagnostics & Bioscience Germany, Siemens Healthcare GmbH, Technology Center, Erlangen, Germany

05/2015 - 10/2016

Senior Key Expert Scientist at Siemens Healthcare GmbH, Technology Center, Erlangen, Germany

05/2007 - 04/2015

Program Manager at Siemens AG, Corp. Technology, Erlangen, Germany

08/2005 - 04/2007

Visiting Scientist at IBM Research GmbH, Zürich Research Laboratory, Rüschlikon, Switzerland

01/2000 - 07/2005

Assistant Professor at the Institute of Analytical Chemistry, University of Vienna, Austria

Awards

2017 - European Inventor Award (category industry for hematology analysis of Plasmodium infections, Patent EP 2 635 695 B1, 2011)

2016 - Innovation Award of AMA (Association for Sensors & Measurement)

2013 - Siemens NTF Award for Medical Imaging IP portfolio 2006 EUREKA Lillehammer Award (E! 2497 Euroenviron BIOMAC) 2002 Young Investigator Award of the Austrian Chemical Society

2000/2001 - Award winner of “Best of Biotech” for start-up competition “Polymimetics”

Research Expertise & Interests

- Current research @ TUM: in vitro & in vivo diagnostics

- Industrial research: 12yrs in the semiconductor and healthcare industry on post-CMOS, medical imaging, in vitro diagnostics, and bioscience topics

- Academic training: 5yrs on piezoacoustic sensing and semiconducting nanowire sensing

>>79360

ANH HOANG

Founder and Chief Science Officer at Sofregen Medical, Framingham, Massachusetts, USA

Dr. Anh Hoang, is the founder of Sofregen Medical, a medical device company that re-invents silk protein for tissue engineering. At Sofregen, Anh currently operates as the chief science officer and serves on the board of directors. Under her leadership, Sofregen obtained the first FDA clearance for the use of re-constituted silk protein for a medical application.

Outside of Sofregen, Anh is a faculty at Massachusetts Institute of Technology’s Catalyst LinQ program . She serves on the Medtech Advisory Group at the Massachusetts Biotechnology Council and on the Steering Committee of MassMedic Ignite Program. She was a recipient of the 2018 Medtech Boston 40 under 40 Healthcare Innovators.

Anh completed her doctorate degree (Ph.D) in material science engineering from Vanderbilt University and her postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital as an Executive Committee on Research fellow. Anh is a proud graduate of Mount Holyoke College where she earned her bachelor’s degree in biochemistry.

>>79361

ANH HOANG

Founder and Chief Science Officer at Sofregen Medical, Framingham, Massachusetts, USA

Dr. Anh Hoang, is the founder of Sofregen Medical, a medical device company that re-invents silk protein for tissue engineering. At Sofregen, Anh currently operates as the chief science officer and serves on the board of directors. Under her leadership, Sofregen obtained the first FDA clearance for the use of re-constituted silk protein for a medical application.

Outside of Sofregen, Anh is a faculty at Massachusetts Institute of Technology’s Catalyst LinQ program . She serves on the Medtech Advisory Group at the Massachusetts Biotechnology Council and on the Steering Committee of MassMedic Ignite Program. She was a recipient of the 2018 Medtech Boston 40 under 40 Healthcare Innovators.

Anh completed her doctorate degree (Ph.D) in material science engineering from Vanderbilt University and her postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital as an Executive Committee on Research fellow. Anh is a proud graduate of Mount Holyoke College where she earned her bachelor’s degree in biochemistry.

LUCIO IANNONE

Senior Director Venture Investments Leaps by Bayer, Cambridge, MA, USA

Lucio Iannone is an investor at Leaps by Bayer, the investment arm of the global life sciences company Bayer. Lucio is responsible for developing investment cases and deal execution. He is also involved in the sourcing, screening, and mentoring of companies with game-changing science. As an investor, Lucio is serving as board member for Pyxis Oncology, Khloris Biosciences, Vesigen Therapeutics , Immunitas Therapeutics, eGenesis, Azitra, Kojin Therapeutics and Axxam. Before joining Leaps by Bayer, he had several senior roles in biotechnology companies and venture capital firms. He has experience with molecular biology, cell & gene therapy technologies and their application in oncology and other therapeutic fields. Lucio obtained his Ph.D. in Medicine at the Imperial College of London and Master in Molecular Biology from Cambridge University.

>>79362

REGINA HODITS

Managing Partner at Wellington Partners Life Sciences (WPLS), Munich, Germany

Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma Therapeutics, ONWARD, Sidekick, SNIPR Biome and STipe Therapeutics. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / Boston Scientific), represented Wellington Partners of the Board of Themis (acquired by MSD), and served as the Spokesperson for the Board of the German PE and VC Association (BVK). Since joining the industry in 2000, she has become an influential investor in the European VC industry, focusing on early-stage and growth deals in Life Sciences.

Before joining WPLS, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was the founding investor in Bicycle Therapeutics (NASDAQ: BCYC), F-star (NASDAQ,: FSTX) and Jenavalve, and served on the Boards of U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), and Novamed (acquired by SciClone NASDAQ SCLN). Before, Regina worked for Apax Partners and McKinsey.

Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry, and was as post-doctoral researcher at the MRC, Cambridge UK.

KATALIN KARIKÓ

Senior Vice President RNA Protein Replacement Therapies at BioNTech, Mainz, Germany

Katalin Karikó is Senior Vice President at BioNTech RNA Pharmaceuticals from 2013. She is also Adjunct Associate Professor at the Perelman School of Medicine, University of Pennsylvania, where she worked for 24 years. She received her PhD in biochemistry from University of Szeged, Hungary, in 1982. For four decades, her research has been focusing on RNA-mediated mechanisms with the ultimate goal of developing in vitro-transcribed mRNA for protein therapy. She investigated RNA-mediated immune activation and co-discovered that nucleoside modifications suppress immunogenicity of RNA. This groundbreaking work unlocked the opportunity for the therapeutic use of mRNA. Her patents, co-invented on nucleoside-modified uridines of mRNA, was the foundation for the FDA-approved anti-SARS-CoV-2 mRNA vaccines developed by BioNTech/Pfizer and Moderna/NIAID that are crucial to ending the global pandemic.

SEKAR KATHIRESAN

CEO at Verve Therapeutics, Cambridge, USA

Sekar Kathiresan is co-founder and chief executive officer of Verve Therapeutics and serves on the company’s board of directors. He is a preventive cardiologist who has made groundbreaking discoveries of cardioprotective genetic mutations, which confer resistance to cardiovascular disease. Prior to joining Verve, he served as director of the Massachusetts General Hospital (MGH) Center for Genomic Medicine and was the Ofer and Shelly Nemirovsky MGH Research Scholar. He also served as director of the Cardiovascular Disease Initiative at the Broad Institute and was professor of medicine at Harvard Medical School. His research laboratory focused on understanding the inherited basis for blood lipids and myocardial infarction and using these insights to improve preventive cardiac care. Among his scientific contributions, he has helped highlight new biological mechanisms underlying heart attack, discovered mutations that protect against heart attack risk, and developed a genetic test for personalized heart attack prevention. He was honored with a Distinguished Scientist Award from the American Heart Association in 2017 and the 2018 Curt Stern Award from the American Society of Human Genetics. In tandem with his research, his clinical focus was the primary prevention of myocardial infarction in individuals with a family history of heart attack. He graduated summa cum laude with a B.A. in history from the University of Pennsylvania and received his M.D. from Harvard Medical School. He completed his clinical training in internal medicine and cardiology at MGH and his postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute.

>>79363

HEYO K. KROEMER

Chief Executive Officer at Charité – Universitätsmedizin Berlin, Germany

A pharmacologist by trade, Prof. Kroemer was born in 1960 in the Eastern Friesland area of Germany, Prof. Kroemer trained as a pharmacologist. From 2000 to 2012, he was Dean of the Medical School at the institution now known as the University of Greifswald. In 2011, he was appointed Scientific Director of Universitätsmedizin Greifswald. After joining the Board in 2007, Prof. Kroemer became President of the German Association of Medical Faculties (MFT) in 2012, a position he held until 2019. During this time, he was both Dean and Chairman of the Board of the University of Göttingen Medical Center. Prof. Kroemer was appointed Charité’s Chief Executive Officer on 1 September 2019.

MADELEINE KÜNZ

Senior Consultant – Market Access & Regulatory Strategie at Kalms Consulting, Berlin

Dr. Madeleine Künz academic background is reseach in Molecular Life Sciences, Structure Biology and Chemistry. Before joining Kalms Consulting, she worked for over 10 years in international research facilities and the pharmaceutical industry. Her research mainly concentrated on rational drug development in international interdisciplinary working groups combining approaches from structural biology, biophysics and chemistry. Her understanding of medical technologies is supported by her additional education and work experience as a paramedic for 7 years as well as advanced education in health technology assessment (HTA). Especially diagnostic but also therapeutic procedures including digital health products are part of her expertise. Furthermore, differentiation as well as compatibility assessments allow her to draw an accurate picture of innovation´s value. Her work in Kalms Consulting is centered around the assessment of innovative technologies and translation of these into options for the regulatory and market access strategy.

JASON LEITCH

National Clinical Director at Scottish Government, Scottland

Jason has worked for the Scottish Government since 2007 and in January 2015 was appointed as The National Clinical Director in the Health and Social Care Directorate. He is a Scottish Government Director and a member of the Health and Social Care Management Board. He is one of the senior team responsible for the NHS in Scotland.

He is an Honorary Professor at the University of Dundee.

Jason was the 2011 UK Clinician of the Year.

He is a Senior Fellow at the Institute for Healthcare Improvement (IHI). He was a 2005-06 Quality Improvement Fellow at IHI, in Boston, sponsored by the Health Foundation.

>>79364

SARAH LEVY-SCHREIER

CTO at Sight Diagnostics

Sarah joined Sight to build and lead its technology dream-team. She is responsible for all of Sight's R&D as well as its medical-regulation activities. Top of her class at the elite Talpiot program, Sarah gained her technology leadership experience during a brilliant military career, where she commanded elite cyber security and intelligence special technology units.

Sarah holds as M.Sc. in Condensed Matter Physics from the Weizmann Instituter of Science, and a B.Sc in Physics & Mathematics (magna cum laude) from the Hebrew University of Jerusalem.

NEEMA MAYHUGH

Managing partner and founder WAVE STRATEGY, Cleveland, Ohio, USA

MANAGING PARTNER

Neema Mayhugh is a healthcare innovation expert who helps large academic medical centers and biotechnology incubators bridge the gap between research and product delivery. Neema designs and executes a comprehensive strategy to take technology from bench to bedside -- engaging partners, securing capital, and delivering desired outcomes, always with an eye toward ensuring the highest quality patient care and enhancing the patient experience.

Built on a solid foundation of clinical innovation, Neema’s expertise stems from strong basic research training and early positions in healthcare management consulting and with Pfizer, Inc. Her specialization then grew rapidly when she joined the industry-leading Cleveland Clinic, where her roles and responsibilities expanded to include:

~ Start-up formation

~ Licensing

~ Intellectual property portfolio prioritization

~ Clinical trial management and execution

~ Sponsored research program negotiation

~ Management of commercialization projects

~ Strategic portfolio oversight

As Chief Operating Officer of Mobile Hyperbaric Centers, Neema expanded her expertise base again, overseeing operations for seven hospital centers and all corporate functions including insurance authorization, billing, documentation, compliance, human resources and center safety and maintenance.

Neema holds a Doctoral degree in Pharmacology & Toxicology from Dartmouth College and a Bachelors of Science in Human Physiology from Boston University.

>>79365

NICHOLAS MILLS

Chair of Cardiology & Consultant Cardiologist at University of Edinburgh

Current post: British Heart Foundation (BHF) Butler Senior Clinical Research Fellow (personal fellowship, 2016-2021) and Personal Chair of Cardiology, BHF/University Centre for Cardiovascular Science, University of Edinburgh. Consultant Interventional Cardiologist, Royal Infirmary of Edinburgh.

Previous appointments:

2013 - 2015 Reader in Cardiology, University of Edinburgh

2011 - 2016 BHF Intermediate Clinical Research Fellow, University of Edinburgh

2011 - 2013 Senior Lecturer in Cardiology, University of Edinburgh

2007 - 2011 Clinical Lecturer in Cardiology, University of Edinburgh

2005 - 2011 Specialist Registrar in Cardiology, Royal Infirmary of Edinburgh

2005 - 2007 Michael Davies/British Cardiac Society Research Fellow, University of Edinburgh

2003 - 2005 British Heart Foundation Research Fellow, Edinburgh University, Edinburgh

2001 - 2003 South East of Scotland Senior House Officer Rotational Training Scheme in Medicine

2000 - 2001 Pre-registration House Officer Posts, Western General Hospital, Edinburgh

Education:

BSc (First Class Honours) Edinburgh University 1998

MB ChB Edinburgh University 2000

MRCP Royal College of Physicians 2003

PhD Edinburgh University 2009

Selected Grants:

British Heart Foundation UK Cardiovascular Regeneration Medicine centre Award Renewal (RM/17/3/33381). 2017 for 4 year (£2.5 million). (Principal Investigator, Prof Andrew Baker).

Duration of dual anti-platelet therapy in acute coronary syndrome across Scotland. The DUAL-ACS2 Trial. BHF Clinical Study Grant (CS/17/4/32960). 2017 for 5 year (£630k). (Principal Investigator, Prof David Newby).

Refining the diagnosis of type 2 myocardial infarction. BHF Clinical Research Training Fellowship (FS/16/75/32533). 2016 for 3 years (£283k) for Dr Andrew Chapman.

High-sensitive cardiac troponin and coronary heart disease. BHF Butler Senior Clinical Research Fellowship (FS/16/14/32023). 2016 for 5 years (£1.2m).

Identification and characterisation of a vessel wall endothelial progenitor cell, and its potential for vascular regeneration. BHF Intermediate Research Fellowship (FS/16/4/31831). 2016 for 4 years (£540k).

High-sensitivity cardiac troponin on presentation to rule out myocardial infarction (HiSTORIC): A randomised controlled trial. BHF Project Grant (PG/15/51/31596). 2015 for 3 years (£272k)

BHF UK Cardiovascular Regenerative Medicine Centre Award (RM/13/2/30158). 2013 for 4 years (£2.5m).

Lipid mediators as predictors of nanoparticle-induced cardiovascular disease. BHF Special Project Grant (SP/15/8/31575). 2015 for 4 years (£538k).

Development of a clinical translational model of arterial injury and repair to assess vascular stem cell therapies. BHF Project Grant. 2013 for 3 years (£299k).

High-sensitive troponin in the evaluation of patients with acute coronary syndrome (HighSTEACS): A randomised controlled trial. BHF Special Project Grant (SP/12/10/29922). 2012 for 3 years (£702k)

>>79366

YAAKOV NAHMIAS

Professor and Director Center for Bioengineering at The Hebrew University of Jerualem, Israel

Prof. Yaakov “Koby” Nahmias is a bioengineer and innovator, whose breakthroughs ranged from the first 3D printing of cells to the first commercial human-on-chip technology. He is a Magna Cum Laude graduate of the Technion, Israel Institute of Technology, and is the founding director of the Grass Center for Bioengineering of the Hebrew University of Jerusalem. Nahmias is a recipient of a NIH career award, two European Research Council (ERC) grants, the Kaye Innovation Award and the prestigious Rappaport Prize in Biomedical Research. He is the first scientist outside Britain to win the Rosetrees Trust Prize. Nahmias is the co-founding director of BioDesign-Israel an entrepreneurship program that educated over 120 fellows, and launching 6 startup companies including Guide In Medical, CardioVia and Swiftduct. Nahmias is the founder and CSO of two biotechnology startups, including Tissue Dynamics that is developing a groundbreaking human-on-chip instruments for drug development, and the Tyson Foods-funded Future Meat Technologies focusing on the cost-effective production of cultured meat.

YORAM PALTI

Professor Emeritus Physiology and Biophysics Technion University, Israel; Founder and Chief Technology Officer Novocure, Israel

Professor Yoram Palti received his M.Sc., Ph.D. and M.D. from The Hebrew University Hadassah Medical School, Jerusalem. He was appointed an Associate Professor of Physiology at the University of Maryland School of Medicine in 1969 and an Assoc Prof. of Physiology and Biophysics at the Technion Medical School in 1971 and Full Prof. in 1976. Currently he is Prof. Emeritus at the Technion.

Palti served as the Head of the Dept. of Physiology & Biophysics (1971- 1991) and as the Head of the Rappaport Family Institute for Research in the Medical Sciences, the research arm of the Technion, from its establishment in 1982 till 1993.

Professor Palti has founded several startup companies, for example: Carmel Biosensors, Echosense, O2Cure, BG Guard and the highly successful Novocure that was established in 2000 and currently has a Cap value of over $20 Billion (NVCR). At NovoCure Palti served as Director through 2018 and serves as the company’s Chief Technology Officer to date.

>>79331

Baker back, lemme collect

>>79367

NINA RAWAL

Founder of Emerging Health Ventures, Stockholm, Sweden

Dr. Nina Rawal is the founder of Emerging Health Ventures. Previously, she headed the life science investment team at Industrifonden, a 600 million EUR venture capital fund. Previous experience also includes of Vice President, Strategy and Ventures at Gambro AB, and management consulting at Boston Consulting Group in Stockholm and New York. She serves on the boards of MedCap AB (publ) and Stockholms Sjukhem, a non-profit hospital and health care organization. She holds a PhD in Molecular Neurobiology, and a MSc in Biomedicine, both from the Karolinska Institute, including research work done at Columbia University in New York and at Hôpital la Salpêtrière in Paris.

Recognition for her work includes the selection as a Young Global Leader by the World Economic Forum and a '40 under 40 - European Young Leader' by Friends of Europe/Europanova.

GUR ROSHWALB

Partner at aMoon, Ra'anana, Israel

Dr. Gur Roshwalb is a Partner at aMoon, where he leads sourcing efforts, leads deals, manages the due diligence process, and sits on the board of AltruBio and Viracta Therapeutics, aMoon Growth portfolio companies. Beginning his career as a practicing physician, Gur understands the urgency driving the innovation in the healthcare industry. He moved to Israel in 2019 to work with aMoon to accelerate HealthTech advances into clinical practice. Gur has over 20 years of healthcare industry and finance experience. Prior to joining aMoon, he was CEO at several private and public biotech companies. Earlier, Gur was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in both private and public companies. Gur started his finance career at Piper Jaffray, where he worked as a vice president and equity analyst, publishing research on specialty pharmaceutical companies. Prior to Piper, Gur was in private practice in New York following residency training in internal medicine at Mount Sinai Medical Center, where he also served as Chief Resident. Gur obtained his medical degree from Albert Einstein College of Medicine of Yeshiva University, his MBA from the NYU Stern School of Business, and a B.A. from Columbia University.

NIELS SHARMAN

Investment Analyst at HTGF, High-Tech Gründerfonds, Bonn, Germany

Niels Sharman is an Investement Analyst within the Life Sciences team of HTGF. He holds a bachelor degree in biology from the Ludwig-Maximilians-University Munich and a master in management from the Technical University Munich. In the past he gained experience in the pharmaceutical industry and contributed to a biotech start-up.

MILDRED Z. SOLOMON

President at The Hastings Center, Garrison, New York USA

Mildred Z. Solomon, EdD is the President of The Hastings Center, the nation’s founding bioethics research institute, focused on examining the social and ethical implications of health and health care, science, and emerging biomedical technologies. She is also Professor (part-time) of Global Health and Social Medicine at Harvard Medical School, where she runs a Fellowship in Bioethics and has trained over 200 scientists, physicians and other kinds of professionals from across the United States and around the world. Dr. Solomon’s own research covers a broad spectrum of topics -- including, for example, the ethics of end-of-life care, organ transplantation, medical professionalism, and responsible conduct of research. She recently completed a two-year term on the World Economic Forum’s Global Futures Council on Technology, Values and Policy. She has served on committees of the National Academies of Sciences, Engineering and Medicine, on the US Secretary of Health and Human Services’ Advisory Committee on Organ Transplantation, and is currently a member of the Global Health Advisory Committee of the Open Society Foundations’ Public Health and Human Rights Programs. Dr. Solomon has over 70 academic publications in peer-reviewed journals and is also frequently cited in the mainstream media, including the Wall Street Journal, National Public Radio, New York Review of Books, The Daily Beast, Forbes, Science News, The Scientist and other outlets. A frequent public speaker, she has presented at Aspen Health, the New York Academy of Sciences, academic medical centers, and numerous public venues. Before leading The Hastings Center, she was Senior Director for Implementation Science at the Association of American Medical Colleges and before that, Vice President of Education Development Center, an independent research institute in Boston, MA. Dr. Solomon holds a B.A from Smith College and a doctorate in educational research methods from Harvard University.

>>79369

ANETTE STRÖH

Project Manager Digital Health and Scouting at BIH Digital Labs, Berlin, Germany

2007 Diploma Product Design, Bauhaus University Weimar

2010 MA Medical Design, Muthesius School of Arts, Kiel

2011-2015 Brand Strategist, f+d design studios, Hamburg

2015 Consultant, diffferent strategy consultancy, Berlin

2015-2017, Design Lead Participatory Health Unit , IXDS, Berlin

2017-2020, Service Design Lead, designit Germany, Berlin

since Dec 2020, Project Manager Digital Health and Scouting, Berlin Institute of Health, Berlin

ALEX WALDRON

CEO at Wellinks, New Haven, Connecticut, USA

Alex Waldron is Chief Executive Officer at Wellinks, a COPD-focused digital health company fueled by a mission to empower people in their pursuit to breathe freely. Wellinks’ lead asset is a digitally enabled and outcomes-driven holistic virtual care management solution for COPD, with a focus on reinventing respiratory care. The company’s expertise in COPD innovation began with the development and FDA 510(k) clearance of Flyp Nebulizer, the first truly pocket-portable nebulizer, allowing patients simple, convenient, and connected access to breathing treatments. Wellinks connects individuals and their caregivers through a suite of medical devices and intuitive software, enabling virtual COPD care management based on information that is real-time, accurate, and actionable.

Executive global bio/pharmaceutical business leader with 25+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations.

JACKIE WARING

Founder & CEO at Investing Women Angels & AccelerateHER, Edinburgh, Founder & CEO at Investing Women Angels & AccelerateHER, Edinburgh, Scotland

Jackie Waring MA (Hons), DMS, DipM, MSc Founder & CEO, Investing Women Angels & AccelerateHER

Jackie is a pioneer of women angels ‘changing the face of angel investing’; bringing more women angels into Scotland’s dynamic angel investment community. An active and experienced angel investor herself; she established and leads Scotland’s all-female angel group Investing Women Angels whose members have invested over 80% of their funds in highly innovative female founded/co-founded companies.

Jackie is an entrepreneur with a passion for helping other entrepreneurs. It was this passion which inspired her to establish AccelerateHER; creating a channel and direct help for female founders going for scale. Publicly recognised by Scotland’s First Minister; she is a major player in shaping the ScotCanDo eco-system. The AccelerateHER Awards, workshops, mentoring and other support are achieving tangible impact; boosting the volume and investment in Scotland’s female-led companies. She has also nurtured strong international partnerships leading to regular AccelerateHER missions to Silicon Valley, Dubai, Berlin; and now Boston and New York in partnership with Founders Forum:

Jackie has previously run three companies, including 10 years CEO of a business/economic development organisation in Scotland. She has also been an external policy advisor to UK government; leading on the access to finance agenda for women entrepreneurs.

RICHARD YOUNG

Professor at Whitehead Institute/MIT, Cambridge, Massachusetts, USA

Richard Young is a Professor at the Whitehead Institute and MIT. Dr. Young studies gene regulation in health and disease and has mentored more than 100 graduate and postdoctoral students, many of whom now lead academic and commercial research programs and enterprises. Young has served as an advisor to the World Health Organization, the National Institutes of Health and numerous scientific societies and journals. His honors include Membership in the National Academy of Sciences and the National Academy of Medicine, and Scientific American has recognized him as one of the top 50 leaders in science, technology and business. He has founded and advised companies in the biotechnology and pharmaceutical industry, and currently serves on the boards of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics and Dewpoint Therapeutics. Young is also an aviator and holds a commercial pilot license.

>>79353

quite rare

https://forebears.io/de/surnames/quandt

Total: 3,022

Frequency:1:26,640

>>79373

JOHN HALLINAN

Chief Development Officer, Danforth Advisors, Waltham, MA

JOHN HALLINAN John Hallinan joined Danforth Advisors in 2020 as the Chief Development Officer. John’s experience in the life sciences reflect positions of increasing responsibility across a broad range of strategic and operational disciplines. His background encompasses venture financings, corporate development, technology licensing, and mergers and acquisitions. Prior to Danforth Advisors, John was the Chief Business Officer at MassBio and Chief Financial Officer at Cytel, a leader in the design and implementation of adaptive clinical trials, and he had been active with MassBio—serving on the Economic Development Advisory Group and as co-chair of the Finance Committee & Entrepreneur’s University. Before joining Cytel, John served as CFO at Signet Laboratories, a leading supplier of diagnostic assays to the pharmaceutical and biotech industries. Prior to Signet, John was interim CFO at Cambium Learning, a private equity-backed publishing company that completed two acquisitions during his tenure. John was the Chief Financial Officer of AnVil, Inc. a venture-funded silico drug discovery company, where he led the company’s healthcare market business development efforts. At CambridgeSoft Corporation, John rose to CFO of that leading biopharma applications and enterprise solutions supplier. As Animation Technologies’ CFO, he guided the company’s first and second rounds of venture funding. John serves on the Advisory Board of the Charité BIH Entrepreneurship Summit and the Advisory Board of the Massachusetts Technology Transfer Center (MTTC), and proud to serve as a mentor in MassCONNECT, the premier mentoring program for early-stage companies and aspiring entrepreneurs.

JOANN HALPERN

Director, Hasso-Plattner-Institut, New York

Dr. Joann Halpern is the New York Director of the Hasso-Plattner-Institut für Digital Engineering (HPI) and an Adjunct Professor of International Education at New York University. Before joining HPI, Halpern lived in Cologne, Germany and helped to prepare a new, global university for accreditation. She moved to Cologne from New York City where she was Founding Director of the German Center for Research and Innovation (GCRI).

Prior to joining the GCRI, Dr. Halpern was Director of Academic Affairs and Senior Studies and Assistant Professor of International Education at Global College of Long Island University. She also co-founded Knowledge Transfer Beyond Boundaries, an NGO with projects in Cameroon, Nigeria, and Yemen. From 1996 to 2001, Halpern was Director of International Programs at Harz University of Applied Sciences in Wernigerode, Germany. She received her B.A. from Dartmouth College, her M.A. from Harvard University, and her Ph.D. from New York University. Dr. Halpern is a recipient of the Harvard Award for Distinction in Teaching as well as scholarships and fellowships from the Fulbright Association, German Academic Exchange Service, Robert Bosch Foundation, and the National Endowment for the Humanities. She serves on the advisory boards of the Charité Entrepreneurship Summit, German Accelerator, Technical University of Dortmund, University Alliance Ruhr, and Virtual Enterprises International.

>>79374

ANULA JAYASURIYA

Founder, eXXclaim Capital, EILSF

Anula Jayasuriya is an experienced health care and Life Sciences executive and investor. Anula’s expertise consists of a unique combination of business, basic science and medical knowledge.

Recognizing the growing yet under-invested opportunity in Women’s Health, in 2013 Anula launched eXXclaim Capital, focused on catalyzing innovation, entrepreneurship and investment in this field and has already made several investments. In 2006 Anula co-founded the “Evolvence India Life Science Fund” (EILSF), to make investments in pharmaceutical, biotechnology, medical device and contract services companies based in India. EILSF has garnered three successful exits to date and India Life Science 11 has had its first close.

She was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German – US venture capital firm TVM, in San Francisco. Her prior positions include VP-Corporate development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation. Anula received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and received an MBA with distinction from Harvard Business School. Anula also has a M. Phil. in pharmacology from the University of Cambridge, in England. Anula sits on the boards of Ocimum BioSolutions, and MapMyGenome, Hyderabad and nVision, San Francisco. She was previously a board member of Health Care Global which was exited to Temasek, Lipomics which was acquired by Tethys and Triesta BioSciences which was acquired by Health Care Global. She also serves on several non-profit boards, including Astia, EPPIC, and The Gruter Institute for Law and Behavioral Research.

MARKUS MÜSCHENICH

Co-Founder & Managing Partner, Flying Health Incubator

Markus Müschenich is a board certified pediatrician and has a degree in Public Health. He is the founder of ConceptHealth, a think tank with longterm expertise in strategic business development based on health care's future foresight analysis. After more than ten years membership of executive boards in private and nonprofit hospital companies, Dr. Müschenich co-founded FLYING HEALTH a German company builder and business developer for health startups. FLYING HEALTH partners with founders, connects geeks and healthcare professionals and supports R&D for innovative products and services gaining market access. Dr. Müschenich is member of the board of directors of the German Association for Internet Medicine.

ANNIKA PIERSON

Annika Pierson, Co-Founder & Chief Operating Officer, Advise Connect Inspire

Through various roles in the German and the US healthcare industries, Annika has extensive experience building strong global networks by bringing together investors, entrepreneurs, and senior industry executives. As Chief Operating Officer of ACI, she facilitates the successful US market entry of emerging companies from Europe and connects US-based startups with European investors and industry groups. Prior to joining the German Accelerator Life Sciences (GALS) and founding ACI in Cambridge, MA, Annika headed the innovation and entrepreneurship programs of Charité Foundation in Berlin, including the highly successful international healthcare industry conference, Charité Entrepreneurship Summit.

JOACHIM RAUTTER

Co-Founder, Peppermint VenturePartners

Joachim Rautter is a co-founder of Peppermint VenturePartners and Managing Partner of Peppermint Charité Biomedical Fund.

Prior to the launch of Peppermint VenturePartners, he was Investment Director at Peppermint Holding GmbH. There he was responsible for the investment activities of the Peppermint Venture Capital Fund. He has over 15 years of experience in the venture capital industry and was Chairman of the Supervisory Board of Scienion AG, as well as Chairman of the Advisory Board of JADO Technologies GmbH and Innolume GmbH. He is currently Chairman of the Board of CEVEC Pharmaceuticals GmbH and CellAct Pharma GmbH, and also serves on the Board of CryoTherapeutics GmbH and Labfolder GmbH.

Prior to joining Peppermint, he guided innovative start-ups in the field of start-up financing and entrepreneurial development. In addition, he was involved in key functions in the design and implementation of regional innovation strategies.

Joachim Rautter has a degree in physics and completed his PhD at the Max Volmer Institute for Biophysical Chemistry at the Technical University of Berlin.

#483

>>79288, >>79303, >>79312, >>79313, >>79315, >>79316, >>79341, >>79349, >>79349, Eyez to the skyz

>>79340 Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.

>>79337, >>79338, >>79342, >>79343, >>79346, >>79347, >>79350, >>79351, >>79352, >>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371, >>79373, >>79374, >>79375, Moar QUANT FAMILY

>>79336 ITALY : SOON Unvaccinated BANNED from Voting

>>79334, >>79335 ‘Unnecessary, misleading, catastrophic’: Senior European physicians co-author expert statement on COVID vaccine for children

>>79333 Senior US diplomat Sherman speaks with Myanmar shadow government

>>79330 Mexico Sues Smith & Wesson and Glock Over Smuggled Firearms

>>79329 The SARS-CoV-2 as an instrumental trigger of autoimmunity

>>79328 Our office recently fought a similar legal challenge to Arizona's election integrity measures and won in the #SCOTUS case 𝑩𝒓𝒏𝒐𝒗𝒊𝒄𝒉 𝒗. 𝑫𝑵𝑪.

>>79326 45 talking congressional wins

>>79314, >>79317 @ORNL, which just got a shipment of advanced fuel rods that went through testing in a commercial reactor.

>>79312 Boeing 737 Max heads to China for key test to end flight ban

>>79309 This is the actual results of the Elections. H/T Scooby Snacks.

>>79307 Baker Hughes Company sold by General Electric Co.: $1.254B-August 3

>>79306 Rebels were, "too powerful to be suppressed by the powers vested in the Marshal of that District." Washington called out the state militias.

>>79305 Introducing wtube.org

>>79299 Fed's Clarida backs raising interest rates in 2023

>>79282 Vote to Remove Gavin Newsom Within Margin of Error; Hispanics Favor Recall

#483

seems diggz should be better organized/labeled

digger lemme know

czech em

>>79350

could you possible break my followup post on Polly out, because it gives an overview? something like this

>>79350, >>79351 Amazing Polly - followup on ENTRUST/Quandts

>>79376

how about a bun for details on Quandts?

>>79378

there are also multiple archived ones

- Foundation Charite, which is separated in speakers 2021 and advisory board, board of trustees, and everything else

- then there is this Jasmin QUANDT Scientist at BioNTech

Bundling everything together is not good imo

>>79379

whatever you think, I don't see how the diggz are divided, you do that with descriptions labels

>>79379

Why though? Simply split them up accordingly.

We don't know for sure if Jasmin Quandt is part of that family, but it's highly likely.

>>79344

i'll make a summary bun, that ok?

>>79384

buns not good, because images are only archived for posts that are directly notabled (and also when they are large enough resolution-wise).

Just split it up directly.

When Q uses all caps

It is usually because the word is an acronym

And each line of a drop is potentially unrelated

Because Q mixes subjects together

So you really have to think

And to dig to find the connections

In these two, I think BIG connects to the images

Not to the other lines in the drop

>>79384

Oh and that Drosten female that got 250.000 EUR from that Quandt-Foundation, that's ALSO separate and it's actually very very important.

>>79389

Can a BV please fix my formatting at the start? 2 "==" are missing.

>>79388

i can't afford to go to portugal.

Despite Deadly Results the FDA will Fast Track Pfizer COVID Vaccine Approval by Early Sept. — Will Allow States and Businesses to Begin their Forced Vaccinations

https://www.thegatewaypundit.com/2021/08/despite-deadly-results-fda-will-fast-track-pfizer-covid-vaccine-approval-early-sept-will-allow-states-businesses-begin-forced-vaccinations/

>>79392

show me exactly what you need done

>>79395

Formatting of this:

Rob QUANDT (Ex-Associate Creative Director Pfizer/AstraZeneca)==

right at the start of the post.

>>79376

>>79385

Organized into categories, can be a bun or just put in notes

plz ck for accuracy

QUANT DIG

>>79337, >>79350, >>79351 Moar Quandt fam - NEW Amazing Polly vid plus notes

>>79338, >>79339 Sandra Ciesek

>>79343, >>79343, >>79352 Foundation Charite

>>79346, >>79347 Jasmin Quandt

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite conference - 2021 speakers

>>79372 How common is the name Quandt? Pretty rare

>>79373, 79374, 7937 Charite Advisory Board Members

>>79397

REVISED

>>79376

>>79385

Organized into categories, can be a bun or just put in notes

plz ck for accuracy

QUANT DIG

>>79337, >>79350 (You), >>79351 (You) Moar Quandt fam - NEW Amazing Polly vid plus notes

>>79338, >>79339 Sandra Ciesek

>>79343, >>79343, >>79352 Foundation Charite

>>79346, >>79347 Jasmin Quandt

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite conference - 2021 speakers

>>79372 How common is the name Quandt? Pretty rare

>>79373, >>79374, 79375 Charite Advisory Board Members

>>79396

>>79395

i see it cakes. logging in nao.

REFRESH

>>79397

Please add Jasmin Quandt - "Scientst at BioNTech, involved in BNT162b2 gene therapy development"

Also add to Sandra Ciesek - "in a team with PCR-test-Drosten, received 250.000 EUR in March from Charite Foundation / Quandt"

Foundation Charite - "2 Quandt family members on the board of trustees"

Charite Advisory Board Members -> Charité Foundation Advisory Board Members

QUANDT DIG

>>79337, >>79350, >>79351 Moar Quandt fam - NEW Amazing Polly vid plus notes

>>79338, >>79339 Sandra Ciesek ( PCR-test-Drosten, rec'd 250.000 EUR from Foundation Charite

>>79343, >>79352 Foundation Charite (2 Quandt fam members on the board)

>>79346, >>79347 Jasmin Quandt - Scientst at BioNTech, involved in BNT162b2 gene therapy development

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite conference - 2021 speakers

>>79372 How common is the name Quandt in Germany? Pretty rare

>>79373, >>79374, >>79375 Charité Foundation Advisory Board Members

>>79373, >>79374, >>79375 Charite Advisory Board Members

>>79389 Rob QUANDT (Ex-Associate Creative Director Pfizer/AstraZeneca)

>>79401

aslo Rob QUANDT has to be added too, I just posted that one

"(Ex-Associate Creative Director Pfizer/AstraZeneca)"

>>79401

hang on

will just edit the post

>>79402

>How common is the name Quandt? Pretty rare

add: "in Germany"!

It's most common in Germany compared to the rest of the world.

#483

>>79288, >>79303, >>79312, >>79313, >>79315, >>79316, >>79341, >>79349, >>79349, Eyez to the skyz

>>79373, >>79374, >>79375 Charite Advisory Board Members

>>79372 How common is the name Quandt? Pretty rare

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite conference - 2021 speakers

>>79346, >>79347 Jasmin Quandt

>>79343, >>79343, >>79352 Foundation Charite

>>79340 Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.

>>79338, >>79339 Sandra Ciesek

>>79337, >>79350, >>79351 Amazing Polly - followup on ENTRUST/Quandts

>>79336 ITALY : SOON Unvaccinated BANNED from Voting

>>79334, >>79335 ‘Unnecessary, misleading, catastrophic’: Senior European physicians co-author expert statement on COVID vaccine for children

>>79333 Senior US diplomat Sherman speaks with Myanmar shadow government

>>79330 Mexico Sues Smith & Wesson and Glock Over Smuggled Firearms

>>79329 The SARS-CoV-2 as an instrumental trigger of autoimmunity

>>79328 Our office recently fought a similar legal challenge to Arizona's election integrity measures and won in the #SCOTUS case 𝑩𝒓𝒏𝒐𝒗𝒊𝒄𝒉 𝒗. 𝑫𝑵𝑪.

>>79326 45 talking congressional wins

>>79314, >>79317 @ORNL, which just got a shipment of advanced fuel rods that went through testing in a commercial reactor.

>>79312 Boeing 737 Max heads to China for key test to end flight ban

>>79309 This is the actual results of the Elections. H/T Scooby Snacks.

>>79307 Baker Hughes Company sold by General Electric Co.: $1.254B-August 3

>>79306 Rebels were, "too powerful to be suppressed by the powers vested in the Marshal of that District." Washington called out the state militias.

>>79305 Introducing wtube.org

>>79299 Fed's Clarida backs raising interest rates in 2023

>>79282 Vote to Remove Gavin Newsom Within Margin of Error; Hispanics Favor Recall

#483

>>79399

bless you

>>79407

I edited this based on anon feedback

>>79402

PLZ REFRESH

sorry for confusing, complicated

>>79409

You decide, you da baker, your call

we diggers do our best

>>79405

tx for getting it all here b4 they do a quick scrub

>>79409

>I edited this based on anon feedback

wasn't really edited??!!

Let me edit these few

>>79407

sore fingers, thinking to get off for a while

u ok?

Updated:

>>79337, >>79350, >>79351 Amazing Polly - followup on ENTRUST/Family Quandts

>>79373, >>79374, >>79375 Charite Foundation Advisory Board Members

>>79372 How common is the name Quandt in Germany? Pretty rare

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite Foundation conference - 2021 speakers

>>79346, >>79347 Jasmin Quandt - Scientist at BioNTech, directly involved in BNT162b2

>>79389 Rob QUANDT (Associate Creative Director at WILDTYPE, Ex-Associate Creative Director Pfizer/AstraZeneca)

>>79343, >>79343, >>79352 Foundation Charite site

>>79340 Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.

>>79338, >>79339 Sandra Ciesek - involved w/ PCR-Test-Drosten, received a grant of 250.000 EUR from Charite Foundation/Johanna-Quandt-Foundation in March 2020

Please verify

>>79413

>involved w/ PCR-Test-Drosten

add:

"found out in February that there would be asymtomatic individuals carrying and spreading the coronavirus"

MOST IMPORTANT

>>79412

I'm fine

diggerz spergin but OK

they've not noticed I stack my notable the other way yet

kek

Updated:

>>79337, >>79350, >>79351 Amazing Polly - followup on ENTRUST/Family Quandts

>>79373, >>79374, >>79375 Charite Foundation Advisory Board Members

>>79372 How common is the name Quandt in Germany? Pretty rare

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite Foundation conference - 2021 speakers

>>79346, >>79347 Jasmin Quandt - Scientist at BioNTech, directly involved in BNT162b2

>>79389 Rob QUANDT (Associate Creative Director at WILDTYPE, Ex-Associate Creative Director Pfizer/AstraZeneca)

>>79343, >>79343, >>79352 Foundation Charite site

>>79340 Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.

>>79338, >>79339 Sandra Ciesek - involved w/ PCR-Test-Drosten, found out in February that there would be asymtomatic individuals carrying and spreading the coronavirus, received a grant of 250.000 EUR from Charite Foundation/Quandts

#483

>>79288, >>79303, >>79312, >>79313, >>79315, >>79316, >>79341, >>79349, >>79349, Eyez to the skyz

>>79337, >>79350, >>79351 Amazing Polly - followup on ENTRUST/Family Quandts

>>79373, >>79374, >>79375 Charite Foundation Advisory Board Members

>>79372 How common is the name Quandt in Germany? Pretty rare

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite Foundation conference - 2021 speakers

>>79346, >>79347 Jasmin Quandt - Scientist at BioNTech, directly involved in BNT162b2

>>79389 Rob QUANDT (Associate Creative Director at WILDTYPE, Ex-Associate Creative Director Pfizer/AstraZeneca)

>>79343, >>79343, >>79352 Foundation Charite site

>>79340 Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.

>>79338, >>79339 Sandra Ciesek - involved w/ PCR-Test-Drosten, found out in February that there would be asymtomatic individuals carrying and spreading the coronavirus, received a grant of 250.000 EUR from Charite Foundation/Quandts

>>79336 ITALY : SOON Unvaccinated BANNED from Voting

>>79334, >>79335 ‘Unnecessary, misleading, catastrophic’: Senior European physicians co-author expert statement on COVID vaccine for children

>>79333 Senior US diplomat Sherman speaks with Myanmar shadow government

>>79330 Mexico Sues Smith & Wesson and Glock Over Smuggled Firearms

>>79329 The SARS-CoV-2 as an instrumental trigger of autoimmunity

>>79328 Our office recently fought a similar legal challenge to Arizona's election integrity measures and won in the #SCOTUS case 𝑩𝒓𝒏𝒐𝒗𝒊𝒄𝒉 𝒗. 𝑫𝑵𝑪.

>>79326 45 talking congressional wins

>>79314, >>79317 @ORNL, which just got a shipment of advanced fuel rods that went through testing in a commercial reactor.

>>79312 Boeing 737 Max heads to China for key test to end flight ban

>>79309 This is the actual results of the Elections. H/T Scooby Snacks.

>>79307 Baker Hughes Company sold by General Electric Co.: $1.254B-August 3

>>79306 Rebels were, "too powerful to be suppressed by the powers vested in the Marshal of that District." Washington called out the state militias.

>>79305 Introducing wtube.org

>>79299 Fed's Clarida backs raising interest rates in 2023

>>79282 Vote to Remove Gavin Newsom Within Margin of Error; Hispanics Favor Recall

#483

all guud?

bake is set

>>79418

LMAO

guud think I got some rest and food huh

>>79411

it was editied if you refresh, although i dropped a parenthesis i'm afraid - just not changed by baker bc he was busy posting notes

this happens often, espec when a lot of info comes in at once

>>79420

blessings cakes

overtime pay due

>>79423

boop on da nose guud enough yo

grin

>>79423

feelz bad on dis end but been wurkfagg'n like a retard all day today.

>>79416

>sperging

well, you're right bout dat

dat's me for shure

concentrating one one thing, ignore another

apologies

>>79426

no problem

kekkin hard

just not the OCD idjit type

muh sides

lemme know if it's guud so I can bake

lord have mercy

Freshness

>>79428

>>79428

>>79428

>>79427

there's a dup here but no biggie

>>79343, >>79343, >>79352 Foundation Charite site